Atara Biotherapeutics Inc (ATRA)
NASDAQ
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Return on Assets (%) | -26.847 | -49.613 | -75.686 | -79.201 | -65.865 | -64.406 | -54.467 | -101.906 |
Return on Equity (%) | -27.793 | -55.371 | -89.293 | -92.426 | -81.427 | -91.688 | -113.23 | -2014.856 |
Return on Invested Capital (%) | -28.578 | -56.515 | -92.292 | -94.382 | -82.449 | -92.466 | -141.798 | -3536.271 |
Operating Margin (%) | N/A | N/A | N/A | N/A | N/A | -1672.05 | -359.099 | -3159.058 |
Net Profit Margin (%) | N/A | N/A | N/A | N/A | N/A | -1672.276 | -361.79 | -3220.88 |
Book Value Per Share | 8.77 | 5.788 | 7.374 | 5.119 | 5.545 | 3.05 | 1.32 | -0.974 |
Earnings Per Share | -2.732 | -3.888 | -5.021 | -5.122 | -3.678 | -3.71 | -2.398 | -2.709 |
Cash Per Share | 1.658 | 2.578 | 1.321 | 1.308 | 2.404 | 1.157 | 0.969 | 0.254 |
Working Capital Per Share | 8.671 | 4.704 | 6.126 | 4.159 | 5.282 | 3.042 | 2.253 | -0.396 |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | 0.222 | 0.663 | -0.003 |
EBIT Per Share | -2.732 | -3.889 | -5.022 | -5.122 | -3.678 | -3.71 | -2.38 | -2.709 |
EBITDA Per Share | -2.732 | -3.889 | -5.022 | -5.122 | -3.678 | -3.71 | -2.38 | -2.709 |
Free Cash Flow Per Share | -2.641 | -3.261 | -4.32 | -5.146 | -3.724 | -3.697 | -2.413 | -2.745 |
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Actions en circulation | 28,93M | 30,73M | 45,95M | 56,81M | 83,37M | 91,67M | 95,93M | N/A |
Fin d'année 31 Décembre 2023 | Déc 2022 | Mar 2023 | Juin 2023 | Sept 2023 | Déc 2023 | Mar 2024 | Juin 2024 | Sept 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Actions en circulation | 95,93M | N/A | N/A | 101,92M | N/A | N/A | N/A | N/A |
Return on Assets (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Equity (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Invested Capital (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Margin (%) | N/A | -5988.01 | N/A | N/A | N/A | -111.763 | N/A | N/A |
Net Profit Margin (%) | N/A | -6098.777 | N/A | N/A | N/A | -116.065 | N/A | N/A |
Sales Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Earnings Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Working Capital Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBIT Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBITDA Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Free Cash Flow Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Capitalisation boursière | 97,05M |
Ratio cours/bénéfice | -0,34 |
Ratio prix/ventes | 11,1 |
Ratio prix/liquidités | 3,68 |
Ratio prix/valeur comptable | -0,96 |
Rendement de dividende | - |
Actions en circulation | 5,76M |
Volume moyen (1 semaine) | 231,25k |
Volume moyen (1 mois) | 124,98k |
Variation sur 52 semaines | 51,69% |
Plus haut sur 52 semaines | 39,50 |
Plus bas sur 52 semaines | 6,50 |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales